

01/14/00  
jc760 U.S. PRO

01-16-00

A

Attorney Docket No.: 5686.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

jc584 U.S. PRO  
09/483504  
01/14/00

Re: U.S. Patent Application for  
Title: Non-Peptide GLP-1 Agonists  
Applicants: Teng et al.

Sir:

Express Mail Label No. EL 473440300US

Date of Deposit : January 14, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Carol McFarlane

(Name of person mailing paper(s) or fee)

Carol McFarlane

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123

09483504-011400

01/14/00  
jc760 U.S. PRO

Attorney Docket No.: 5686.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL 473440300US  
Date of Deposit January 14, 2000

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of  
Applicant(s): Teng et al.

Title: Non-Peptide GLP-1 Agonists

187 pages of specification 1 page of abstract

5 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: 15 - 20 = 0 x 18 =	\$0
Independent Claims: 1 - 3 = 0 x 78 =	\$0
Total Fee:	\$690.00

Priority of Danish application no. PA 1999 00041 filed on January 15, 1999 is  
claimed under 35 U.S.C. 119. A certified copy will follow herewith.


Priority of U.S. provisional application no. 60/116,116 filed on January 15, 1999 is  
claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of  
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 14, 2000

  
Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

004470-409E8460